These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
197 related articles for article (PubMed ID: 23148684)
1. Unique functions of CHK1 and WEE1 underlie synergistic anti-tumor activity upon pharmacologic inhibition. Guertin AD; Martin MM; Roberts B; Hurd M; Qu X; Miselis NR; Liu Y; Li J; Feldman I; Benita Y; Bloecher A; Toniatti C; Shumway SD Cancer Cell Int; 2012 Nov; 12(1):45. PubMed ID: 23148684 [TBL] [Abstract][Full Text] [Related]
2. Combined inhibition of Wee1 and Chk1 gives synergistic DNA damage in S-phase due to distinct regulation of CDK activity and CDC45 loading. Hauge S; Naucke C; Hasvold G; Joel M; Rødland GE; Juzenas P; Stokke T; Syljuåsen RG Oncotarget; 2017 Feb; 8(7):10966-10979. PubMed ID: 28030798 [TBL] [Abstract][Full Text] [Related]
3. Chk1 and Wee1 control genotoxic-stress induced G2-M arrest in melanoma cells. Vera J; Raatz Y; Wolkenhauer O; Kottek T; Bhattacharya A; Simon JC; Kunz M Cell Signal; 2015 May; 27(5):951-60. PubMed ID: 25683911 [TBL] [Abstract][Full Text] [Related]
4. Preclinical evaluation of the WEE1 inhibitor MK-1775 as single-agent anticancer therapy. Guertin AD; Li J; Liu Y; Hurd MS; Schuller AG; Long B; Hirsch HA; Feldman I; Benita Y; Toniatti C; Zawel L; Fawell SE; Gilliland DG; Shumway SD Mol Cancer Ther; 2013 Aug; 12(8):1442-52. PubMed ID: 23699655 [TBL] [Abstract][Full Text] [Related]
5. A subset of cancer cell lines is acutely sensitive to the Chk1 inhibitor MK-8776 as monotherapy due to CDK2 activation in S phase. Sakurikar N; Thompson R; Montano R; Eastman A Oncotarget; 2016 Jan; 7(2):1380-94. PubMed ID: 26595527 [TBL] [Abstract][Full Text] [Related]
6. Combined inhibition of Chk1 and Wee1 as a new therapeutic strategy for mantle cell lymphoma. Chilà R; Basana A; Lupi M; Guffanti F; Gaudio E; Rinaldi A; Cascione L; Restelli V; Tarantelli C; Bertoni F; Damia G; Carrassa L Oncotarget; 2015 Feb; 6(5):3394-408. PubMed ID: 25428911 [TBL] [Abstract][Full Text] [Related]
7. CHK1 plays a critical role in the anti-leukemic activity of the wee1 inhibitor MK-1775 in acute myeloid leukemia cells. Qi W; Xie C; Li C; Caldwell JT; Edwards H; Taub JW; Wang Y; Lin H; Ge Y J Hematol Oncol; 2014 Aug; 7():53. PubMed ID: 25084614 [TBL] [Abstract][Full Text] [Related]
8. Combined inhibition of Chk1 and Wee1: in vitro synergistic effect translates to tumor growth inhibition in vivo. Carrassa L; Chilà R; Lupi M; Ricci F; Celenza C; Mazzoletti M; Broggini M; Damia G Cell Cycle; 2012 Jul; 11(13):2507-17. PubMed ID: 22713237 [TBL] [Abstract][Full Text] [Related]
10. Knockdown of Chk1, Wee1 and Myt1 by RNA interference abrogates G2 checkpoint and induces apoptosis. Wang Y; Decker SJ; Sebolt-Leopold J Cancer Biol Ther; 2004 Mar; 3(3):305-13. PubMed ID: 14726685 [TBL] [Abstract][Full Text] [Related]
11. Combination therapy targeting the Chk1 and Wee1 kinases shows therapeutic efficacy in neuroblastoma. Russell MR; Levin K; Rader J; Belcastro L; Li Y; Martinez D; Pawel B; Shumway SD; Maris JM; Cole KA Cancer Res; 2013 Jan; 73(2):776-84. PubMed ID: 23135916 [TBL] [Abstract][Full Text] [Related]
12. Chk1 inhibition and Wee1 inhibition combine synergistically to impede cellular proliferation. Davies KD; Cable PL; Garrus JE; Sullivan FX; von Carlowitz I; Huerou YL; Wallace E; Woessner RD; Gross S Cancer Biol Ther; 2011 Nov; 12(9):788-96. PubMed ID: 21892012 [TBL] [Abstract][Full Text] [Related]
13. Pharmacological inactivation of CHK1 and WEE1 induces mitotic catastrophe in nasopharyngeal carcinoma cells. Mak JP; Man WY; Chow JP; Ma HT; Poon RY Oncotarget; 2015 Aug; 6(25):21074-84. PubMed ID: 26025928 [TBL] [Abstract][Full Text] [Related]
14. Targeting replication stress response using polypurine reverse hoogsteen hairpins directed against WEE1 and CHK1 genes in human cancer cells. Aubets E; Noé V; Ciudad CJ Biochem Pharmacol; 2020 May; 175():113911. PubMed ID: 32173365 [TBL] [Abstract][Full Text] [Related]
15. G2-checkpoint targeting and radiosensitization of HPV/p16-positive HNSCC cells through the inhibition of Chk1 and Wee1. Busch CJ; Kröger MS; Jensen J; Kriegs M; Gatzemeier F; Petersen C; Münscher A; Rothkamm K; Rieckmann T Radiother Oncol; 2017 Feb; 122(2):260-266. PubMed ID: 27939202 [TBL] [Abstract][Full Text] [Related]
16. Synergism Through WEE1 and CHK1 Inhibition in Acute Lymphoblastic Leukemia. Ghelli Luserna Di Rorà A; Bocconcelli M; Ferrari A; Terragna C; Bruno S; Imbrogno E; Beeharry N; Robustelli V; Ghetti M; Napolitano R; Chirumbolo G; Marconi G; Papayannidis C; Paolini S; Sartor C; Simonetti G; Yen TJ; Martinelli G Cancers (Basel); 2019 Oct; 11(11):. PubMed ID: 31717700 [TBL] [Abstract][Full Text] [Related]
17. Synergistic anti-leukemic interactions between panobinostat and MK-1775 in acute myeloid leukemia ex vivo. Qi W; Zhang W; Edwards H; Chu R; Madlambayan GJ; Taub JW; Wang Z; Wang Y; Li C; Lin H; Ge Y Cancer Biol Ther; 2015; 16(12):1784-93. PubMed ID: 26529495 [TBL] [Abstract][Full Text] [Related]
18. Cytokinetic effects of Wee1 disruption in pancreatic cancer. Chang Q; Chandrashekhar M; Ketela T; Fedyshyn Y; Moffat J; Hedley D Cell Cycle; 2016; 15(4):593-604. PubMed ID: 26890070 [TBL] [Abstract][Full Text] [Related]
19. Synergistic antitumor interactions between MK-1775 and panobinostat in preclinical models of pancreatic cancer. Wang G; Niu X; Zhang W; Caldwell JT; Edwards H; Chen W; Taub JW; Zhao L; Ge Y Cancer Lett; 2015 Jan; 356(2 Pt B):656-68. PubMed ID: 25458954 [TBL] [Abstract][Full Text] [Related]
20. Targeting histone deacetylases (HDACs) and Wee1 for treating high-risk neuroblastoma. Hanmod SS; Wang G; Edwards H; Buck SA; Ge Y; Taub JW; Wang Z Pediatr Blood Cancer; 2015 Jan; 62(1):52-9. PubMed ID: 25308916 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]